2
Orphan Designations
0 approved, 2 designated
0
FDA Approvals
2
Active Trials
200 recruiting
2
Rare Diseases
across 4 areas
0
News (30d)
Quiet
Satellos Bioscience Inc. is a company with 2 orphan drug designations across 2 rare diseases. Active clinical trials in 2 indications. 5 active policy bills affect their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| Becker muscular dystrophy | heterocyclic small molecule kinase inhibitor of a Notch associated kinase that enhances satellite cell driven regeneration of muscle | Des.TrialAppr. |
| Duchenne muscular dystrophy | small molecule inhibitor of AAK1, a protein kinase member of the Notch pathwayheterocyclic small molecule kinase inhibitor of a Notch associated kinase that enhances satellite cell driven regeneration of muscle | Des.TrialAppr. |
| muscular dystrophy | - | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
48
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
5
affecting portfolio
0% of portfolio targets high unmet need diseases
48
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
5
affecting portfolio